Lung Cancer

Thursday, May 3, 2018 from 10:15 AM to 11:45 AM
Available for up to 1.50 hours of CPE credit
Activity Number: 0217-9999-18-073-L01-P

Sara K. Butler, Pharm.D., BCPS, BCOP

  • Faculty: Sara K. Butler, Pharm.D., BCPS, BCOP
    Clinical Pharmacy Specialist, Medical Oncology Clinical Oncology Supervisor PGY-2 Oncology Residency Program Director Barnes-Jewish Hospital St. Louis, Missouri
      View Biography

Learning Objectives
1. Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lung cancer.
2. Identify relevant cancer-related molecular biology testing for a patient with lung cancer.
3. Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer and supportive-care agents for a patient with lung cancer.
4. Select relevant information and guidance for the public regarding lung cancer-related issues (e.g., risk factors, prevention, screening).
5. Devise and communicate appropriate plans for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lung cancer, including pulmonary toxicities from PD1 inhibitors.
6. Develop and communicate a prevention and management strategy for chemotherapy-induced nausea and vomiting for patients with any type of cancer.
© 2019 American College of Clinical Pharmacy and American Society of Health‑System Pharmacists